Health
MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials – News-Medical.Net
A new study reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against SARS-CoV-2, the agent that is causing the current COVID-19 pandemic….
The modified vaccina virus Ankara (MVA) is an attenuated vaccinia virus that has been used as a vector in the already approved Adenovirus-MVA-based Ebola vaccine. A new preprint appearing on the bioRxiv* server reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that is causing the current coronavirus disease 2019 (COVID-19) pandemic. The MVA provides a vector platform for the rapid production…
-
General24 hours agoBill Shorten believes Peter Dutton’s work-from-home policy backflip will cost him at election time
-
Noosa News24 hours ago$100 Million Cavill Avenue revamp set to reshape Surfers Paradise
-
Noosa News23 hours agoAudit slams state school fees
-
General16 hours agoVolodymyr Zelenskyy says 155 Chinese nationals fighting with Russia in Ukraine